Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04925193 · ClinicalTrials.gov registry record · Phase 2

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

A Phase 2 study of Multiple Myeloma in Relapse, sponsored by University of Colorado, Denver.

Active
Registry status
Phase 2
Development phase
18
Enrollment target
1
Study location

NCT04925193 is a Phase 2 study of Multiple Myeloma in Relapse that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 18 participants, below the 50-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04925193, a Phase 2 study of Multiple Myeloma in Relapse, is active but no longer recruiting, sponsored by University of Colorado, Denver.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to evaluate the outcomes achieved with selinexor based combination in RRMM selected by physician's choice and compared prospectively to ex vivo drug sensitivity testing results. Participants will be enrolled and assigned into one of three treatment selection groups. The study sample size was powered to analyze the total group of patients enrolled. It was not powered to analyze each treatment regimen individually. Selection groups are as follows: Group 1: Selinexor + pomalidomide + dexamethasone (SPd) Group 2: Selinexor + daratumumab + dexamethasone (SDd) Group 3: Selinexor + carfilzomib + dexamethasone (SKd)

Conditions Studied

Multiple Myeloma in Relapse

Interventions

  • DRUG Selinexor
  • DRUG Dexamethasone
  • DRUG Daratumumab
  • DRUG Pomalidomide
  • DRUG Carfilzomib

Study Locations (1)

Colorado

  • University of Colorado Hospital - Aurora

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2021-11-18
Est. Completion 2026-11
Phase Phase 2

Sponsor

University of Colorado, Denver

1,283 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04925193

The ClinicalTrials.gov registry entry for NCT04925193 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 50-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (64% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma in Relapse appearing as the primary indexed condition, and to 5 interventions - of which Selinexor is the first listed.

NCT04925193 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT04925193 about?

NCT04925193 is a clinical study titled "Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma". Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to evaluate the outcomes achieved with selinexor based combination in RRMM selected by physician's choice and...

What is the current status of trial NCT04925193?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2021-11-18. Estimated completion is 2026-11.

What conditions does trial NCT04925193 study?

This clinical trial studies the following conditions: Multiple Myeloma in Relapse.

What interventions are being tested in trial NCT04925193?

The interventions under investigation include: Selinexor (DRUG), Dexamethasone (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Carfilzomib (DRUG).

Who is sponsoring clinical trial NCT04925193?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04925193 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma in Relapse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma in Relapse

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.